Adagrasib(Krazati)
Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection
Validity period:
The shelf life of KRAZATI is 24 months when stored under proper conditions.
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of
a
pharmacist. For read by medical and pharmaceutical professionals only.
Adagrasib, branded as KRAZATI, is an oral medication that targets KRAS G12C mutations, offering a targeted therapy option for patients with KRAS G12C-mutated non-small cell lung cancer and colorectal cancer. The drug works by irreversibly inhibiting the mutated KRAS protein, blocking its abnormal signaling pathway, and inhibiting tumor growth.
It is used both as a single agent for NSCLC and in combination with cetuximab for the treatment of CRC. It has shown promising results in clinical trials, providing a treatment option for patients with limited alternatives due to previous systemic therapies.
Generic name
Adagrasib(Krazati)
Alternative Names
Krazati
Indications
KRAZATI (adagrasib) is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) that harbor the KRAS G12C mutation. This includes patients who have received at least one prior systemic therapy.
Therapeutic Target
KRAS G12C
Active Ingredients
Adagrasib
Description
KRAZATI (adagrasib) is a selective, small-molecule inhibitor of the KRAS G12C mutation. The drug specifically targets and irreversibly inhibits the mutated KRAS protein, which is a key driver in the pathogenesis of certain cancers, particularly NSCLC. By binding to the cysteine residue at the G12C mutation site, KRAZATI prevents the activation of downstream signaling pathways responsible for cell growth and survival, thus inhibiting tumor progression. This targeted approach distinguishes KRAZATI from traditional chemotherapies.
Dosage and Administration
Recommended Dose: The recommended dose of KRAZATI is 600 mg orally once daily.
Administration: KRAZATI should be taken with or without food. Tablets should be swallowed whole and not crushed or chewed.
Missed Dose: If a dose is missed, the patient should take it as soon as possible on the same day, unless it is near the time for the next dose. Do not take two doses at the same time.
Contact Us
Mailbox:Info@Lucius.La
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved
